These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8292716)

  • 1. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin.
    Wesselschmidt R; Likert K; Huang Z; MacPhail L; Broze GJ
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):661-9. PubMed ID: 8292716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.
    Cunningham AC; Hasty KA; Enghild JJ; Mast AE
    Biochem J; 2002 Oct; 367(Pt 2):451-8. PubMed ID: 12117418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa.
    Peraramelli S; Suylen DP; Rosing J; Hackeng TM
    Thromb Haemost; 2012 Aug; 108(2):266-76. PubMed ID: 22627666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: a comparison between tissue factor pathway inhibitor and inactive factor VIIa.
    Valentin S; Reutlingsperger CP; Nordfang O; Lindhout T
    Thromb Haemost; 1995 Dec; 74(6):1478-85. PubMed ID: 8772224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profiling of recombinant tissue factor pathway inhibitor.
    Jeske W; Hoppensteadt D; Callas D; Koza MJ; Fareed J
    Semin Thromb Hemost; 1996; 22(2):213-9. PubMed ID: 8807720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue factor pathway inhibitor; its structure, function and clinical significance.
    Kato H
    Pol J Pharmacol; 1996; 48(1):67-72. PubMed ID: 9112630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.
    Johnson K; Zaror I; Bauer D; Choi Y; Creasey A; Innis M
    Thromb Haemost; 1998 Oct; 80(4):585-7. PubMed ID: 9798974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa.
    Wesselschmidt R; Likert K; Girard T; Wun TC; Broze GJ
    Blood; 1992 Apr; 79(8):2004-10. PubMed ID: 1562726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding.
    Piro O; Broze GJ
    Circulation; 2004 Dec; 110(23):3567-72. PubMed ID: 15557366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor Xa enhances the binding of tissue factor pathway inhibitor to acidic phospholipids.
    Valentin S; Schousboe I
    Thromb Haemost; 1996 May; 75(5):796-800. PubMed ID: 8725726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa.
    Burgering MJ; Orbons LP; van der Doelen A; Mulders J; Theunissen HJ; Grootenhuis PD; Bode W; Huber R; Stubbs MT
    J Mol Biol; 1997 Jun; 269(3):395-407. PubMed ID: 9199408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site.
    Enjyoji K; Miyata T; Kamikubo Y; Kato H
    Biochemistry; 1995 May; 34(17):5725-35. PubMed ID: 7727433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of the binding of factor Xa to phospholipids in the inhibitory mechanism of tissue factor pathway inhibitor: the transmembrane and cytoplasmic domains of tissue factor are not essential for the inhibitory action of tissue factor pathway inhibitor.
    Kazama Y
    Thromb Haemost; 1997 Mar; 77(3):492-7. PubMed ID: 9066000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor.
    Iakhiaev A; Ruf W; Rao LV
    Thromb Haemost; 2001 Mar; 85(3):458-63. PubMed ID: 11307815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins.
    Valentin S; Nordfang O; Bregengård C; Wildgoose P
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):713-20. PubMed ID: 8292720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient high affinity binding of tissue factor pathway inhibitor-factor Xa complexes to negatively charged phospholipid membranes.
    Willems GM; Janssen MP; Salemink I; Wun TC; Lindhout T
    Biochemistry; 1998 Mar; 37(10):3321-8. PubMed ID: 9521652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor.
    Lindhout T; Franssen J; Willems G
    Thromb Haemost; 1995 Sep; 74(3):910-5. PubMed ID: 8571320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The lipoprotein-associated coagulation inhibitor.
    Broze GJ; Girard TJ; Novotny WF
    Prog Hemost Thromb; 1991; 10():243-68. PubMed ID: 2008533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure and biology of tissue factor pathway inhibitor.
    Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
    Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor.
    Lockett JM; Mast AE
    Biochemistry; 2002 Apr; 41(15):4989-97. PubMed ID: 11939795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.